Citations

Showing 10 of 108094 citations.

Treatment of the extrahepatic manifestations of chronic hepatitis C infection
Wijarnpreecha, Karn , Cheungpasitporn, Wisit , Pungpapong, Surakit , Nakkala, Kiran, Cheungpasitporn, Wisit , Pungpapong, Surakit , Wijarnpreecha, Karn

Mayo Clinic

Clinical Liver Disease | June 6, 2018 | Volume: 11 | Issue: 5 | Pages: 115-118

10.1002/cld.705 | PMID 30992800 Get It

Ketamine Use in the Intensive Care Unit
Wieruszewski, Patrick M. , Leung, Jonathan G. , Nelson, Sarah , Leung, Jonathan G , Wieruszewski, Patrick M

Mayo Clinic

AACN Advanced Critical Care | June 6, 2018 | Volume: 29 | Issue: 2 | Pages: 101-106

10.4037/aacnacc2018448 | PMID 29875104 Get It

Aspiring to an improved aspiration literature
Kallmes, David F. , Ansari, Sameer A. , Liebeskind, David S. , Zaidat, Osama O. , Ansari, Sameer A , Liebeskind, David S. , Siddiqui, Adnan H.

Mayo Clinic

Journal of NeuroInterventional Surgery | June 6, 2018 | Volume: 10 | Issue: 10 | Pages: 923-924

10.1136/neurintsurg-2018-014046 | PMID 29875275 Get It

Consideration for Circadian Physiology in Rodent Research
Matveyenko, Aleksey V.

Mayo Clinic

Physiology | June 6, 2018 | Volume: 33 | Issue: 4 | Pages: 250-251

10.1152/physiol.00012.2018 | PMID 29873599 Get It

Association of antidiabetic medication use, cognitive decline, and risk of cognitive impairment in older people with type 2 diabetes: Results from the population‐based Mayo Clinic Study of Aging
Wennberg, Alexandra , Hagen, Clinton E., Edwards, Kelly K., Roberts, Rosebud O., Petersen, Ronald C. , Mielke, Michelle M. , Wennberg, Alexandra M V , Edwards, Kelly, Mielke, Michelle M , Machulda, Mary M. , Knopman, David S.

Mayo Clinic

International Journal of Geriatric Psychiatry | June 6, 2018 | Volume: 33 | Issue: 8 | Pages: 1114-1120

10.1002/gps.4900 | PMID 29873112 Get It

ObjectiveTo determine the cross‐sectional and longitudinal associations between diabetes treatment type and cognitive outcomes among type II diabetics.MethodsWe examined the association between metformin use, as compared to other diabetic treatment (ie, insulin, other oral medications, and diet/exercise) and cognitive test performance and mild cognitive impairment (MCI) diagnosis among 508 cognitively unimpaired at baseline type II diabetics enrolled in the Mayo Clinic Study of Aging. We created propensity scores to adjust for treatment effects. We used multivariate linear and logistic regression models to investigate the cross‐sectional association between treatment type and cognitive test z scores, respectively. Mixed effects models and competing risk regression models were used to determine the longitudinal association between treatment type and change in cognitive test z scores and risk of developing incident MCI.ResultsIn linear regression analyses adjusted for age, sex, education, body mass index, APOE ε4, insulin treatment, medical comorbidities, number of medications, duration of diabetes, and propensity score, we did not observe an association between metformin use and cognitive test performance. Additionally, we did not observe an association between metformin use and cognitive test performance over time (median = 3.7‐year follow‐up). Metformin was associated with an increased risk of MCI (subhazard ratio (SHR) = 2.75; 95% CI = 1.64, 4.63, P < .001). Similarly, other oral medications (SHR = 1.96; 95% CI = 1.19, 3.25; P = .009) and insulin (SHR = 3.17; 95% CI = 1.27, 7.92; P = .014) use were also associated with risk of MCI diagnosis.ConclusionsThese findings suggest that metformin use, as compared to management of diabetes with other treatments, is not associated with cognitive test performance. However, metformin was associated with incident MCI diagnosis.
Vasodilator-Stimulated Phosphoprotein Biomarkers Are Associated with Invasion and Metastasis in Colorectal Cancer
Pitari, Giovanni M. , Cotzia, Paolo , Ali, Mehboob , Rizzo, Wendy, Bombonati, Alessandro, Palazzo, Juan , Solomides, Charalambos , Shuber, Anthony P., Zuzga, David S., Birbe, Ruth , Sinicrope, Frank A.

Mayo Clinic

Biomarkers in Cancer | June 6, 2018 | Volume: 10 | Issue: No issue available | Pages: No page available

10.1177/1179299x18774551 | PMID 30911223 Get It

Background and Aims: The benefit of adjuvant chemotherapy for stage II colorectal cancer (CRC) patients remains unclear, emphasizing the need for improved prognostic biomarkers to identify patients at risk of metastatic recurrence. To address this unmet clinical need, we examined the expression and phosphorylation status of the vasodilator-stimulated phosphoprotein (VASP) in CRC tumor progression. VASP, a processive actin polymerase, promotes the formation of invasive membrane structures leading to extracellular matrix remodeling and tumor invasion. Phosphorylation of VASP serine (Ser) residues 157 and 239 regulate VASP function, directing subcellular localization and inhibiting actin polymerization, respectively. Methods: The expression levels of VASP protein, pSer157-VASP, and pSer239-VASP were determined by immunohistochemistry in tumors and matched normal adjacent tissue from 141 CRC patients, divided into 2 cohorts, and the association of VASP biomarker expression with clinicopathologic features and disease recurrence was examined. Results: We report that changes in VASP expression and phosphorylation were significantly associated with tumor invasion and disease recurrence. Furthermore, we disclose a novel 2-tiered methodology to maximize VASP positive and negative predictive value performance for prognostication. Conclusion: VASP biomarkers may serve as prognostic biomarkers in CRC and should be evaluated in a larger clinical study.
Gastrointestinal: Hide‐bound bowel
Hoversten, Patrick , Bledsoe, Adam C. , Sweetser, Seth

Mayo Clinic

Journal of Gastroenterology and Hepatology | June 6, 2018 | Volume: 33 | Issue: 8 | Pages: 1433-1433

10.1111/jgh.14283 | PMID 29873115 Get It

Climate change and atopic dermatitis: is there a link?
Nguyen, Giang Huong , Andersen, Louise K. , Davis, Mark , Nguyen, Giang Huong , Davis, Mark Denis P., Nguyen, Giang H

Mayo Clinic

International Journal of Dermatology | June 6, 2018 | Volume: 58 | Issue: 3 | Pages: 279-282

10.1111/ijd.14016 | PMID 29873062 Get It

Effect of ionic strength on shear-thinning nanoclay–polymer composite hydrogels
Sheikhi, Amir , Afewerki, Samson , Öklü, Rahmi , Gaharwar, Akhilesh K. , Khademhosseini, Ali , Khademhosseini, Ali , Oklu, Rahmi , Khademhosseini, Ali , Khademhosseini, Ali

Mayo Clinic

Biomaterials Science | June 6, 2018 | Volume: 6 | Issue: 8 | Pages: 2073-2083

10.1039/c8bm00469b | PMID 29944151 Get It

The effect of ionic strength on the structure and rheological properties of nanoclay–gelatin shear-thinning biomaterials (STBs) is investigated. A fundamental insight into nanoclay–polymer interactions in physiological environments is provided to design clay-based biomaterials for biomedical applications.
Impact of Powdered Vancomycin on Preventing Surgical Site Infections in Neurosurgery: A Systematic Review and Meta-analysis
Texakalidis, Pavlos , Lu, Victor M. , Yolcu, Yagiz U. , Kerezoudis, Panagiotis , Alvi, Mohammed Ali , Fogelson, Jeremy L. , Bydon, Mohamad , Yolcu, Yagiz, Parney, Ian F. , Alvi, Mohammed Ali

Mayo Clinic

Neurosurgery | June 5, 2018 | Volume: 84 | Issue: 3 | Pages: 569-580

10.1093/neuros/nyy288 | PMID 29982615 Get It

Abstract BACKGROUND Surgical site infections (SSIs) after spine and brain surgery present a major burden to patients and hospitals by increasing morbidity, mortality, and healthcare costs. OBJECTIVE To review available literature investigating the role of intrawound powdered vancomycin against SSIs after neurosurgical operations. METHODS All randomized and observational English language studies of intrawound powdered vancomycin use in spinal and cranial surgery were included and analyzed using random-effects modeling. RESULTS In spine surgery (25 studies with 16 369 patients), patients in the vancomycin group had a significantly lower risk for any SSI (odds ratio [OR]: 0.41; 95% confidence interval [CI]: 0.30-0.57; P < .001; I 2 = 47%). However, when separate analyses were conducted for superficial and deep SSIs, a significant difference was found only for deep (OR: 0.31; 95% CI: 0.22-0.45; P < .001; I 2 = 29%). Subgroup analyses for different vancomycin powder dosages (1 g vs 2 g vs composite dose) did not point to any dose-related effect of vancomycin. In cranial surgery (6 studies with 1777 patients), use of vancomycin was associated with a significantly lower risk for SSIs (OR: 0.33; 95% CI: 0.18-0.60; P = .0003; I 2 = 45%). In meta-regression analysis, trial-level variability of diabetes had no influence on the association of vancomycin powder use with SSIs. CONCLUSION Use of vancomycin powder in spinal and cranial surgery might be protective against SSIs, especially against deep SSIs. No dose-related effect of vancomycin powder was identified. However, caution is needed in the clinical interpretation of these results, owing to the observational design of the included studies in this meta-analysis.